Monday, July 30, 2012

KEEPING YOU IN THE LOOP...Recent Clinical Trial Updates


FDA Approves Prescription-Grade Fish Oil studied in the PMG Network.

The FDA has approved Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an accompaniment to diet to reduce triglyceride (TG) levels in adult patients with severe (TG greater than or equal to 500 mg/dL) hypertriglyceridemia. 
Congratulations to all of the participants that contributed to the development of a new high triglyceride medication through their participation in Amarin clinical trials with PMG!  Thanks to all of the PMG sites that worked so hard on the Vascepa projects as well! To learn more please click here.

Biocryst announces positive results from Two Ulodesine Phase 2 Trials in patients with Gout  studied across the PMG Network.
Gout is a chronic inflammatory arthritis. When people suffer from gout it is because they have much higher levels of uric acid than is normally the case. This condition is known as hyperuricemia which occurs because the body is not able to break down such high levels of uric acid.
Ulodesine is a once-daily oral dosing suitable for chronic administration added to allopurinol to treat gout. Read more for more details about this study.

No comments :

Post a Comment

Subscribe Via Email